Overview

Clinical Efficacy and Safety of Dendritic Cytotoxic Lymphocyte(DC-CTL) Cell Infusion in NSCLC Patients

Status:
Unknown status
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
Patients in group A will receive DC-CTL treatment and chemotherapy. Patients in group B will receive only chemotherapy.
Phase:
Phase 2
Details
Lead Sponsor:
Shenzhen Hornetcorn Bio-technology Company, LTD
Treatments:
Cisplatin
Gemcitabine